VEEV

Veeva Systems (VEEV) closed at $316.80, up 2.08% and outperforming the S&P 500. The cloud-based life sciences software provider gained 19.27% over the past month.

Analysts expect Q earnings of $2.33 per share (up 14.22% YoY) and full-year earnings of $9.22 per share (up 13.83% YoY). The stock holds a Zacks Rank #3 (Hold) with a Forward P/E of 33.67 and PEG ratio of 0.96, trading at a premium to its industry average.

Veeva Systems (VEEV), a cloud-based software provider for the life sciences industry, has outperformed the broader market with a +12.3% return over the past month. The company shows strong earnings growth of +14.2% year-over-year for the current quarter and consistent revenue growth of +15.1%. However, with a Zacks Rank #3 (Hold) rating and a D valuation grade indicating premium pricing relative to peers, the stock is expected to perform in line with the broader market in the near term.

Veeva Systems expanded its partnership with IQVIA, with IQVIA selecting additional Veeva clinical operations applications as enterprise standards for clinical development studies. The agreement covers CTMS, eTMF, Study Startup, and Site Connect tools, building on their previous EDC partnership. This expansion is expected to strengthen Veeva's presence in clinical research, improve trial efficiency, and create cross-selling opportunities, though financial terms and deployment timelines were not disclosed.

Veeva Systems closed at $301.63, up 1.95% and outperforming the broader market decline. The stock has gained 11.36% over the past month, significantly outpacing the Medical sector's 1.06% gain.

Upcoming earnings are expected to show 14.22% EPS growth and 15.11% revenue growth quarter-over-quarter, with full-year projections of $9.22 EPS and $3.69 billion revenue. The company holds a Zacks Rank of #3 (Hold) with a Forward P/E of 32.09, trading in line with its industry average.

Veeva Systems announced that over 175 emerging biotech companies are adopting Veeva Basics to streamline drug development operations. The pre-configured platform helps smaller biotechs establish technology infrastructure for clinical, regulatory, and quality processes. Growing adoption could support long-term revenue growth as these companies expand, though financial impact depends on customer retention and conversion to meaningful revenue.

Veeva Systems (VEEV) delivered strong Q2 fiscal 2027 results, beating estimates and raising its full-year outlook, driven by expanding Vault CRM adoption with 12 of top 20 biopharmas committed and over 180 customers live. The company is advancing AI initiatives with Veeva Falcon attracting early adopters. However, market saturation in the life sciences CRM space and intensifying competition from traditional and AI-powered platforms could constrain future growth rates.

Veeva Systems' Data Quality System (DQS) platform has expanded its reach to support data cleaning across over 1,000 clinical studies involving more than 1 million subjects, generating 500,000+ automated queries. The platform's integration with AI, CTMS, and Study Builder Agent is expected to drive deeper customer engagement and recurring revenue growth in the life sciences software market.

Nike shares fell 3.6% after missing Q4 fiscal 2026 revenue estimates with $11.21 billion in sales. Synaptics surged 14.1% following ON Semiconductor's revised $5.7 billion acquisition terms.

NVIDIA rose 1.3% after reaching a new all-time intraday high of $237.87. Veeva Systems declined 3.1% as healthcare emerged as a losing sector.

Veeva Systems (VEEV) closed down 3.08% to $273.25, underperforming the S&P 500's 0.73% gain. The cloud-based life sciences software provider is projected to report 14.22% EPS growth and 15.11% revenue growth in the upcoming quarter. With a Forward P/E of 30.58 (below industry average of 31.16) and a PEG ratio of 0.87, the stock holds a Zacks Rank #3 (Hold) rating.

Veeva Systems stock declined 1.23% to $281.93 while the broader market gained, underperforming the S&P 500's 0.2% gain. Despite the daily decline, VEEV has risen 1.68% over the past month, outperforming its Medical sector.

The company is expected to report strong earnings growth of 14.22% EPS and 15.11% revenue growth, with full-year projections showing 13.83% earnings and 15.35% revenue increases. VEEV holds a Zacks Rank #3 (Hold) with a Forward P/E of 30.96, trading at a discount to its industry average, and a favorable PEG ratio of 0.88.

Veeva Systems, a cloud-based software provider for the life sciences industry, is trending among investors. The stock has returned +1.7% over the past month, outperforming the S&P 500's -0.4% change.

With earnings expected to grow 13.8% this fiscal year and 10.2% next year, along with strong revenue growth forecasts of 15.3% and 12% respectively, Veeva has consistently beaten consensus estimates. However, the stock carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation (Grade D) compared to peers, suggesting it may perform in line with the broader market in the near term.

While Wall Street brokers maintain a strong buy-equivalent average recommendation (ABR of 1.85) for Veeva Systems with 55.6% Strong Buy ratings, the Zacks Rank assigns the stock a Hold rating (#3). The article cautions that brokerage recommendations often carry positive bias due to vested interests, and notes that Veeva's unchanged consensus earnings estimate of $9.22 suggests the stock may perform in line with the broader market in the near term.

The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, expanding at a 20.2% CAGR. Growth is driven by rising chronic disease management demand, expanding reimbursement coverage, and maturing wearable sensor technology, enabling a shift from episodic facility-centered care to continuous connected care models.

iOnctura, a clinical-stage precision oncology company, announced the appointment of Paul Sekhri as Chair of its Board of Directors. Sekhri brings over 35 years of life science executive experience and has led multiple biotech companies through commercialization.

The appointment comes as iOnctura prepares for late-stage development of roginolisib, its lead PI3Kδ inhibitor candidate, with two randomized Phase II studies fully enrolled. Roginolisib has shown promising clinical signals including doubled overall survival in uveal melanoma compared to historical controls.

The global Decentralized Clinical Trials (DCT) market is valued at $8.8 billion in 2025 and is projected to reach $18.8 billion by 2030, growing at a 13.7% CAGR. Growth is driven by AI integration, wearable technologies, cloud-based platforms, and increased adoption of remote research capabilities across pharmaceutical, biotechnology, and contract research sectors.

The VanEck Morningstar Wide Moat ETF (MOAT) is a smart beta ETF launched in 2012 that tracks companies with sustainable competitive advantages. With $11.46 billion in assets and a 0.46% expense ratio, it offers medium-risk exposure primarily to Information Technology, Healthcare, and Consumer Staples sectors.

Year-to-date returns are 4.06% with a 7.97% one-year return. The article compares it to lower-cost alternatives like IVV and VOO, which track the S&P 500 with 0.03% expense ratios.